stockrow
Saturday 7 November 2026
Export XFOR’s income statement to Excel — free account
X4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.
- Revenue
- +63.1%
- EPS
- +76.9%
- Free cash flow
- +27.5%
- Total debt
- +1.24%
Quarter to September 2026, against a year earlier
3.15
0.08
+2.61%
Follow XFOR
Alert me
X4 Pharmaceuticals, Inc. (XFOR) P/E ratio
X4 Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 11.0× (July 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 11.0×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNTC Benitec Biopharma Limited compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. compare | 6.6× |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)